Posaconazole for treatment of refractory invasive fungal disease.
Invasive fungal infections are usually associated with immunocompromised states About 40-60% of these patients are refractory to standard antifungal therapy We describe the effect of posaconazole in the treatment of a 12 years-old girl with uncontrolled diabetes mellitus with life-threatening cerebral mucor mycosis and a 4 year old girl boy with chronic granulomatous disease presenting with invasive Aspergillus nidulans infection.
Notheis
G
G
University Childrens Hospital, Munich, Germany.
Tarani
L
L
Costantino
F
F
Jansson
A
A
Rosenecker
J
J
Friederici
D
D
Belohradsky
B H
BH
Reinhardt
D
D
Seger
R
R
Schweinitz
D V
DV
Wintergerst
Uwe
U
D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001233:Aspergillus nidulans / Q000187:drug effects / Q000302:isolation & purification; D020314:Central Nervous System Fungal Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D025141:Drug Resistance, Fungal; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000150:complications; D006801:Humans; D016867:Immunocompromised Host; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology; D012233:Rhizopus / Q000187:drug effects / Q000302:isolation & purification; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole